1
|
Sucharski HC, Dudley EK, Williams J, Dewal R, Stanford KI, Mohler PJ, Koenig SN. Abstract 423: Imatinib Promotes Reverse Cholesterol Transport And Elevates Sr-bi. Arterioscler Thromb Vasc Biol 2022. [DOI: 10.1161/atvb.42.suppl_1.423] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/05/2022]
Abstract
Dyslipidemia is a cardiovascular risk factor for coronary artery disease and atherosclerosis that is characterized by elevated serum cholesterol and lipid levels. Although high-density lipoprotein-associated cholesterol (HDL-C) is associated with reduced risk of cardiovascular events, targeted therapy to increase HDL-C levels have been unsuccessful in altering outcomes of associated atherosclerotic disease. Single nucleotide polymorphisms in
SCARB1
, the gene that encodes HDL receptor Scavenger Receptor B1 (SR-BI), are associated with dyslipidemia and atherosclerotic cardiovascular disease. We were the first to identify inherited mutations in
SCARB1
that segregate with disease in a family with severe coronary artery disease and dyslipidemia, including elevated HDL. Our findings suggest that HDL function (vs. HDL-C concentration) may be a promising target for cholesterol-based therapy. Here, we performed an unbiased high throughput drug screen with 788 FDA-approved compounds, using HepG2 cells to measure endogenous HDL binding. We identified five compounds that significantly increased endogenous HDL binding: imatinib, trimethoprim, eszopiclone, clemastine, and mepenzolate, of which, imatinib was the only compound to increase SR-BI expression. Imatinib is a tyrosine kinase inhibitor that is a chemotherapeutic agent designed to treat individuals with chronic myeloid leukemia. Limited clinical evidence suggests a reduction in total cholesterol with 400mg/day imatinib. Additionally, imatinib treatment (150mg/kg) in mouse models of atherosclerosis reduces total cholesterol. Yet, no data is available on the effects of imatinib on HDL and reverse cholesterol transport. We have found that imatinib promotes HDL binding and SR-BI expression
in vitro
. Furthermore, in wildtype C57Bl/6 mice on a high fat, high cholesterol diet, imatinib treatment (50mg/kg) was sufficient to decrease plasma total cholesterol, HDL-C and triglyceride levels and elevate hepatic SR-BI expression. In summary, our data supports the exploration of imatinib-mediated SR-BI regulation, HDL metabolism, and RCT pathway to identify new therapeutic targets for dyslipidemia.
Collapse
|
2
|
Koenig SN, Sucharski HC, Jose EM, Dudley EK, Madiai F, Cavus O, Argall AD, Williams JL, Murphy NP, Keith CBR, Refaey ME, Gumina RJ, Boudoulas KD, Milks MW, Sofowora G, Smith SA, Hund TJ, Wright NT, Bradley EA, Zareba KM, Wold LE, Mazzaferri EL, Mohler PJ. Inherited Variants in SCARB1 Cause Severe Early-Onset Coronary Artery Disease. Circ Res 2021; 129:296-307. [PMID: 33975440 PMCID: PMC8273129 DOI: 10.1161/circresaha.120.318793] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
[Figure: see text].
Collapse
Affiliation(s)
- Sara N. Koenig
- Dorothy M. Davis Heart and Lung Research Institute and Frick Center for Heart Failure and Arrhythmia Research, The Ohio State University, Columbus, OH 43210
- Department of Physiology and Cell Biology, The Ohio State University, Columbus, OH 43210
| | - Holly C. Sucharski
- Dorothy M. Davis Heart and Lung Research Institute and Frick Center for Heart Failure and Arrhythmia Research, The Ohio State University, Columbus, OH 43210
- Department of Physiology and Cell Biology, The Ohio State University, Columbus, OH 43210
| | - Elizabeth M. Jose
- Dorothy M. Davis Heart and Lung Research Institute and Frick Center for Heart Failure and Arrhythmia Research, The Ohio State University, Columbus, OH 43210
- Department of Physiology and Cell Biology, The Ohio State University, Columbus, OH 43210
| | - Emma K. Dudley
- Dorothy M. Davis Heart and Lung Research Institute and Frick Center for Heart Failure and Arrhythmia Research, The Ohio State University, Columbus, OH 43210
- Department of Physiology and Cell Biology, The Ohio State University, Columbus, OH 43210
| | - Francesca Madiai
- Dorothy M. Davis Heart and Lung Research Institute and Frick Center for Heart Failure and Arrhythmia Research, The Ohio State University, Columbus, OH 43210
- Ross Heart Hospital, The Ohio State University College of Medicine and Wexner Medical Center, Columbus, OH 43210
| | - Omer Cavus
- Dorothy M. Davis Heart and Lung Research Institute and Frick Center for Heart Failure and Arrhythmia Research, The Ohio State University, Columbus, OH 43210
- Department of Physiology and Cell Biology, The Ohio State University, Columbus, OH 43210
| | - Aaron D. Argall
- Dorothy M. Davis Heart and Lung Research Institute and Frick Center for Heart Failure and Arrhythmia Research, The Ohio State University, Columbus, OH 43210
- Department of Physiology and Cell Biology, The Ohio State University, Columbus, OH 43210
| | - Jordan L. Williams
- Dorothy M. Davis Heart and Lung Research Institute and Frick Center for Heart Failure and Arrhythmia Research, The Ohio State University, Columbus, OH 43210
- Department of Physiology and Cell Biology, The Ohio State University, Columbus, OH 43210
| | - Nathaniel P. Murphy
- Dorothy M. Davis Heart and Lung Research Institute and Frick Center for Heart Failure and Arrhythmia Research, The Ohio State University, Columbus, OH 43210
- Department of Physiology and Cell Biology, The Ohio State University, Columbus, OH 43210
| | - Caullin B. R. Keith
- Dorothy M. Davis Heart and Lung Research Institute and Frick Center for Heart Failure and Arrhythmia Research, The Ohio State University, Columbus, OH 43210
- Department of Physiology and Cell Biology, The Ohio State University, Columbus, OH 43210
| | - Mona El Refaey
- Dorothy M. Davis Heart and Lung Research Institute and Frick Center for Heart Failure and Arrhythmia Research, The Ohio State University, Columbus, OH 43210
- Department of Physiology and Cell Biology, The Ohio State University, Columbus, OH 43210
| | - Richard J. Gumina
- Dorothy M. Davis Heart and Lung Research Institute and Frick Center for Heart Failure and Arrhythmia Research, The Ohio State University, Columbus, OH 43210
- Ross Heart Hospital, The Ohio State University College of Medicine and Wexner Medical Center, Columbus, OH 43210
| | - Konstantinos D. Boudoulas
- Ross Heart Hospital, The Ohio State University College of Medicine and Wexner Medical Center, Columbus, OH 43210
| | - M. Wesley Milks
- Ross Heart Hospital, The Ohio State University College of Medicine and Wexner Medical Center, Columbus, OH 43210
| | - Gbemiga Sofowora
- Ross Heart Hospital, The Ohio State University College of Medicine and Wexner Medical Center, Columbus, OH 43210
| | - Sakima A. Smith
- Dorothy M. Davis Heart and Lung Research Institute and Frick Center for Heart Failure and Arrhythmia Research, The Ohio State University, Columbus, OH 43210
- Department of Physiology and Cell Biology, The Ohio State University, Columbus, OH 43210
- Ross Heart Hospital, The Ohio State University College of Medicine and Wexner Medical Center, Columbus, OH 43210
| | - Thomas J. Hund
- Dorothy M. Davis Heart and Lung Research Institute and Frick Center for Heart Failure and Arrhythmia Research, The Ohio State University, Columbus, OH 43210
- Department of Physiology and Cell Biology, The Ohio State University, Columbus, OH 43210
| | - Nathan T. Wright
- Department of Chemistry and Biochemistry, James Madison University, Harrisonburg, VA 22807
| | - Elisa A. Bradley
- Dorothy M. Davis Heart and Lung Research Institute and Frick Center for Heart Failure and Arrhythmia Research, The Ohio State University, Columbus, OH 43210
- Ross Heart Hospital, The Ohio State University College of Medicine and Wexner Medical Center, Columbus, OH 43210
| | - Karolina M. Zareba
- Ross Heart Hospital, The Ohio State University College of Medicine and Wexner Medical Center, Columbus, OH 43210
| | - Loren E. Wold
- Dorothy M. Davis Heart and Lung Research Institute and Frick Center for Heart Failure and Arrhythmia Research, The Ohio State University, Columbus, OH 43210
- Department of Physiology and Cell Biology, The Ohio State University, Columbus, OH 43210
- College of Nursing, The Ohio State University, Columbus, OH 43210
| | - Ernest L. Mazzaferri
- Dorothy M. Davis Heart and Lung Research Institute and Frick Center for Heart Failure and Arrhythmia Research, The Ohio State University, Columbus, OH 43210
- Ross Heart Hospital, The Ohio State University College of Medicine and Wexner Medical Center, Columbus, OH 43210
| | - Peter J. Mohler
- Dorothy M. Davis Heart and Lung Research Institute and Frick Center for Heart Failure and Arrhythmia Research, The Ohio State University, Columbus, OH 43210
- Department of Physiology and Cell Biology, The Ohio State University, Columbus, OH 43210
- Ross Heart Hospital, The Ohio State University College of Medicine and Wexner Medical Center, Columbus, OH 43210
| |
Collapse
|